Disease Information

General Information of the Disease (ID: DIS00375)

• Name: Gastrointestinal system cancer
• ICD: ICD-11: 2C11

Type(s) of Resistant Mechanism of This Disease

  RTDM: Regulation by the Disease Microenvironment

Drug Resistance Data Categorized by Drug

Clinical Trial Drug(s) 1 drug(s) in total

Capivasertib

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Regulation by the Disease Microenvironment (RTDM)

Key Molecule: PI3-kinase alpha (PIK3CA) [1]

• Sensitive Disease: Gastrointestinal system cancer [ICD-11: 2C11.Y]
• Sensitive Drug: Capivasertib
• Molecule Alteration: Missense mutation; p.E542K (c.1624G>A)
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Stomach; N.A.
• In Vivo Model: GC xenograft (PDGCX) mouse model; Mus musculus
• Experiment for Molecule Alteration: Western blot analysis
• Experiment for Drug Resistance: MTS assay

Key Molecule: PI3-kinase alpha (PIK3CA) [1]

• Sensitive Disease: Gastrointestinal system cancer [ICD-11: 2C11.Y]
• Sensitive Drug: Capivasertib
• Molecule Alteration: Missense mutation; p.E545K (c.1633G>A)
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Stomach; N.A.
• In Vivo Model: GC xenograft (PDGCX) mouse model; Mus musculus
• Experiment for Molecule Alteration: Western blot analysis
• Experiment for Drug Resistance: MTS assay

References

• Ref 1: The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to TaxotereJ Transl Med. 2013 Oct 2;11:241. doi: 10.1186/1479-5876-11-241.